Jazz Pharmaceuticals acquired Chimerix in April 2025, and the FDA granted accelerated approval to Jazz Pharma's therapy on the same date.
1 report, 1 independent
Updated Aug 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jazz Pharmaceuticals acquired Chimerix in April 2025, and the FDA granted accelerated approval to Jazz Pharma's therapy on the same date.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Jazz Pharmaceuticals
Irish tax-registered pharmaceutical corporation
-
Chimerix (United States)
company in Durham, United States
Nothing else this week.
- FDA
Related events
Coverage
Newest first; wire copies grouped- Pharmaceutical TechnologyFDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy The US Food and Drug Administration (FDA) has given accelerated approval to Jazz Pharmaceuticals for Modeyso (dordavipro